분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2017-12-20 13:04:01 , Hit : 258
 Spark Therapeutics shares rise on FDA approval of new gene therapy for blindness

https://www.marketwatch.com/story/spark-therapeutics-shares-rise-on-fda-approval-of-new-gene-therapy-for-blindness-2017-12-19-1191742

Published: Dec 19, 2017 11:07 a.m. ET  

By Emma Court
Reporter

Spark Therapeutics Inc. ONCE, -0.22% shares rose 3% in heavy morning trade Tuesday after the company's gene therapy Luxturna was approved by the Food and Drug Administration for a rare type of inherited vision loss. Just one administration of the therapy could treat the disease, making it a major scientific breakthrough. The approval had been widely expected after an FDA committee recommended it in October, and was heralded by FDA Commissioner Scott Gottlieb as "another first in the field of gene therapy." The next, major question for the therapy is price, with some analysts projecting the cost could come close to $1 million. Gene therapies, the first of which was approved this past summer, are expected to challenge existing U.S. payment structures with their price tags, which are extremely high and cover a one-time treatment. Luxturna was approved for individuals with confirmed biallelic RPE65 mutation-associated retinal dystrophy, which is part of a group of eye disorders caused by gene mutations, can cause complete blindness in some cases and affects about 1,000 to 2,000 people in the U.S. Spark shares have plummeted 41.5% over the last three months, compared with a 7.2% rise in the S&P 500 SPX, -0.32% and a 10.8% rise in the Dow Jones Industrial Average DJIA, -0.15%







1246   Lenvima OK'd as First-Line Treatment for Unresectable Hepatocellular Carcinoma  이성욱 2018/08/19 106
1245   [바이오토픽] 유전자를 침묵시키는 신약, 20년의 기다림 끝에 승인  이성욱 2018/08/13 105
1244   Doubts arise again about CRISR'd human embryos  이성욱 2018/08/09 124
1243   CRISPR-Cas12a More Precise Than CRISPR-Cas9  이성욱 2018/08/07 122
1242   Lethal Viruses Hijack DNA-Damage Response, May Be Exploited for Cancer  이성욱 2018/08/07 105
1241   Ruling on gene editing crops a threat to innovation and future food security, scientists say  이성욱 2018/07/28 94
1240   Another "CRISPR Calamity"? U.K. Team Reports CRISPR-Induced Gene Rearrangements  이성욱 2018/07/17 121
1239   Cause of CRISPR Failure Identified and Reversed  이성욱 2018/07/12 138
1238   CRISPR Efficiency Tied to Cancer-Causing Process  이성욱 2018/06/13 168
1237   Gene Therapy Ever More Common for Rare Disorders  이성욱 2018/05/30 168
1236   RNA World May Have Started Spinning with Triplet-Based Synthesis  이성욱 2018/05/21 161
1235   CRISPR’s MAGESTIC Evolution Makes Gene Editing More Precise  이성욱 2018/05/08 249
1234   CRISPR-Cas9 Improved 10,000-Fold by Synthetic Nucleotides  이성욱 2018/04/17 259
1233   Nature Methods retracts CRISPR study  이성욱 2018/04/10 462
1232   릴리 '시람자' 간암 말기 임상시험 성공  이성욱 2018/04/07 294
1231   Powerful enzyme could make CRISPR gene-editing more versatile  이성욱 2018/03/01 295
1230   Severe Toxicity Reported in High-Dose AAV Gene Therapy in Animals  이성욱 2018/02/01 484
1229   Shields Up for New Cancer Gene-Therapy Virus  이성욱 2018/02/01 382
1228   JPM서 논란 ‘유전자가위 기술’ 올해의 마일스톤은?  이성욱 2018/01/21 476
1227   암 면역요법, 일부 환자에게만 효과 있는 이유  이성욱 2018/01/12 462

[1] 2 [3][4][5][6][7][8][9][10]..[64] [다음 10개]
 

Copyright 1999-2019 Zeroboard / skin by ROBIN